Advertisement


Eyal Meiri, MD, on Pembrolizumab in Colorectal Cancer: Results From the TAPUR Study

2020 Gastrointestinal Cancers Symposium

Advertisement

Eyal Meiri, MD, of the Cancer Treatment Centers of America at Southeastern Regional Medical Center, discusses his findings on heavily pretreated patients with colorectal cancer with high tumor mutational burden. Monotherapy with pembrolizumab showed antitumor activity, which merits further study to confirm efficacy (Abstract 133).



Related Videos

Colorectal Cancer
Immunotherapy

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy

Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, discusses how treating microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal ca...

Colorectal Cancer

Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool

Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cance...

Hepatobiliary Cancer
Immunotherapy

Thomas Yau, MBBS, on Advanced Hepatocellular Carcinoma: CheckMate 040 Trial of Nivolumab, Ipilimumab, and Cabozantinib

Thomas Yau, MBBS, of the University of Hong Kong, discusses this triplet combination, which yielded better responses than doublet combination therapy in patients with advance...

Colorectal Cancer

Scott Kopetz, MD, PhD, on Metastatic Colorectal Cancer: Quality of Life Results on Encorafenib, Cetuximab, and Binimetinib

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the BEACON CRC trial, which had demonstrated that the triplet r...

Pancreatic Cancer

Eileen M. O’Reilly, MD, on Pancreatic Adenocarcinoma: Gemcitabine, Cisplatin, and Veliparib

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceed...

Advertisement

Advertisement



Advertisement